Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder | MicrobiomeTrials← Back to trialsNCT07809724
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-08-30Est. Completion: 2028-08-15
Enrollment target: 60 participants Locations- Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
NMOSDNeuromyelitis Optica Spectrum Disorder
The primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), an…
Beijing, ChinaEst. completion Sep 19, 2028
Progressive Multiple Sclerosis (PMS)Neuromyelitis OpticaMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseAutoimmune EncephalitisStiff-Person Syndrome
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary effi…
Multiple LocationsEst. completion Dec 30, 2029